Aviron Message Board - Msg: 2203798

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron

AVIR 3.375

+1.7%

Nov 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (135)	9/16/1997 2:59:00 AM
From: Vector1	of 645

PB, the results from AVIR's recent pivotal trial is being presented today (the 16th) at 11:00am PSTat the Infectious Disease Society of America conference in San Fran. According to H&Q and Robby Stephens the abstacts for the meeting which were distributed a few days ago (prob the cause of the big rn up last week) support the conclusion that the vaccine will have a major impact on the influenza market beginning in the 99 season. The abstacts contain some additional info; The most important new info is that there was veryhigh single dose efficacy with one dose agianst both stains of flu that were prevelent during the 96-97 season. Although young children will reeive two doses their first year of vaccination, the single dose efficcy is supportive for vaccination of older kids and healthy adults and the elderly. in addition the company has commenced several new major studies this season including a large multicenter trial in adults exploring endpoints such as workplace absenteeism and use of health care workers. Upcoming events include, initiation of Phase I/II trial with EBV vaccine expected in 3q97 and initiation of phase III study of CAIV in elderly patients in q3. The NDA should be in mid 98. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next